Drug Profile
MTX 211
Alternative Names: MTX-211Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Mekanistic Therapeutics; University of Michigan
- Developer Mekanistic Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (PO)
- 01 Apr 2017 Preclinical trials in Colorectal cancer in USA (PO)
- 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from preclinical studies in Colorectal cancer presented at the 108th Annual Meeting of the American Association for Cancer Research